Understanding the relationship between GSK-3 and Alzheimer’s disease: a focus on how GSK-3 can modulate synaptic plasticity processes

Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease

(2012) Miguel Medina et al.   CURRENT PHARMACEUTICAL DESIGN

Inhibition of Glycogen Synthase Kinase-3 Ameliorates β-Amyloid Pathology and Restores Lysosomal Acidification and Mammalian Target of Rapamycin Activity in the Alzheimer Disease Mouse Model

(2012) Limor Avrahami et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Interaction of Endogenous Tau Protein with Synaptic Proteins Is Regulated byN-Methyl-d-aspartate Receptor-dependent Tau Phosphorylation

(2012) Siddhartha Mondragón-Rodríguez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes

(2012) Philip T.T. Ly et al.   JOURNAL OF CLINICAL INVESTIGATION

Selectively Silencing GSK-3 Isoforms Reduces Plaques and Tangles in Mouse Models of Alzheimer's Disease

(2012) D. E. Hurtado et al.   JOURNAL OF NEUROSCIENCE

Glycogen Synthase Kinase 3 Inhibition Promotes Lysosomal Biogenesis and Autophagic Degradation of the Amyloid-  Precursor Protein

(2012) C. Parr et al.   MOLECULAR AND CELLULAR BIOLOGY

Selective deletion of forebrain glycogen synthase kinase 3  reveals a central role in serotonin-sensitive anxiety and social behaviour

(2012) C. Latapy et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Neurological Functions of the Masterswitch Protein Kinase – Gsk-3

(2012) Oksana Kaidanovich-Beilin et al.   Frontiers in Molecular Neuroscience

GSK-3β and memory formation

(2012) Akihiko Takashima   Frontiers in Molecular Neuroscience

A pivotal role of GSK-3 in synaptic plasticity

(2012) Clarrisa A. Bradley et al.   Frontiers in Molecular Neuroscience

New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors

(2012) Michael Maes et al.   INFLAMMOPHARMACOLOGY

Association analysis of GSK3B and MAPT polymorphisms with Alzheimer's disease in Han Chinese

(2011) Na Zhang et al.   BRAIN RESEARCH

Functional significance of glycogen synthase kinase-3 regulation by serotonin

(2011) Abigail M. Polter et al.   CELLULAR SIGNALLING

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

(2011) Xiyun Chai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health

(2011) Jean-Martin Beaulieu   JOURNAL OF PSYCHIATRY & NEUROSCIENCE

GSK-3α/β kinases and amyloid production in vivo

(2011) Tomasz Jaworski et al.   NATURE

Aβ1–42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β

(2011) Jihoon Jo et al.   NATURE NEUROSCIENCE

Calpain regulates N-terminal interaction of GSK-3β with 14-3-3ζ, p53 and PKB but not with axin

(2011) Paloma Goñi-Oliver et al.   NEUROCHEMISTRY INTERNATIONAL

The Inflammatory Response to Double Stranded DNA in Endothelial Cells Is Mediated by NFκB and TNFα

(2011) Suraj J. Patel et al.   PLoS One

The Cell Biology of Synaptic Plasticity

(2011) V. M. Ho et al.   SCIENCE

Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies

(2011) Miguel Medina et al.   Frontiers in Molecular Neuroscience

Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models

(2010) Lars M. Ittner et al.   CELL

Glycogen synthase kinase-3β, or a link between amyloid and tau pathology?

(2010) D. Muyllaert et al.   GENES BRAIN AND BEHAVIOR

Regulation of AMPA Receptor Trafficking and Function by Glycogen Synthase Kinase 3

(2010) Jing Wei et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

(2010) A. Boutajangout et al.   JOURNAL OF NEUROSCIENCE

Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease

(2010) Lars M. Ittner et al.   NATURE REVIEWS NEUROSCIENCE

Long-term depression in the CNS

(2010) Graham L. Collingridge et al.   NATURE REVIEWS NEUROSCIENCE

Alzheimer's Disease

(2010) Henry W. Querfurth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation of GABAergic synapse formation and plasticity by GSK3 -dependent phosphorylation of gephyrin

(2010) S. K. Tyagarajan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of GSK-3 Ameliorates Aβ Pathology in an Adult-Onset Drosophila Model of Alzheimer's Disease

(2010) Oyinkan Sofola et al.   PLoS Genetics

Mechanisms of tau-induced neurodegeneration

(2009) Khalid Iqbal et al.   ACTA NEUROPATHOLOGICA

Blocked Inhibitory Serine-Phosphorylation of Glycogen Synthase Kinase-3α/β Impairs In Vivo Neural Precursor Cell Proliferation

(2009) Tae-Yeon Eom et al.   BIOLOGICAL PSYCHIATRY

Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders

(2009) Rakez Kayed et al.   CURRENT OPINION IN IMMUNOLOGY

GSK3: A possible link between beta amyloid peptide and tau protein

(2009) Félix Hernández et al.   EXPERIMENTAL NEUROLOGY

Propagation of Tau Misfolding from the Outside to the Inside of a Cell

(2009) Bess Frost et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Αβ Hinders Nuclear Targeting of AICD and Fe65 in Primary Neuronal Cultures

(2009) A. G. Henriques et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Transmission and spreading of tauopathy in transgenic mouse brain

(2009) Florence Clavaguera et al.   NATURE CELL BIOLOGY

GSK-3 is a master regulator of neural progenitor homeostasis

(2009) Woo-Yang Kim et al.   NATURE NEUROSCIENCE

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

(2009) Kurt R. Brunden et al.   NATURE REVIEWS DRUG DISCOVERY

A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases

(2009) Stéphane Peineau et al.   Molecular Brain

Abnormalities in brain structure and behavior in GSK-3alpha mutant mice

(2009) Oksana Kaidanovich-Beilin et al.   Molecular Brain

Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK-3β) and Alzheimer’s disease risk

(2008) I. Mateo et al.   ACTA NEUROLOGICA SCANDINAVICA

Glycogen synthase kinase-3β and tau genes interact in Alzheimer's disease

(2008) John B. J. Kwok et al.   ANNALS OF NEUROLOGY

Association of GSK3B With Alzheimer Disease and Frontotemporal Dementia

(2008) Barbara A. J. Schaffer et al.   ARCHIVES OF NEUROLOGY

Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior

(2008) Dennis J. Selkoe   BEHAVIOURAL BRAIN RESEARCH

The role of GSK-3 in synaptic plasticity

(2008) S Peineau et al.   BRITISH JOURNAL OF PHARMACOLOGY

Amyloid-β Binds to the Extracellular Cysteine-rich Domain of Frizzled and Inhibits Wnt/β-Catenin Signaling

(2008) Margaret H. Magdesian et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells

(2008) A. Gómez-Ramos et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

GSK-3β Is Required for Memory Reconsolidation in Adult Brain

(2008) Tetsuya Kimura et al.   PLoS One

Role of GSK3  in behavioral abnormalities induced by serotonin deficiency

(2008) J.-M. Beaulieu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA